KT-474 has exceeded the Phase 1 target degradation of 85% to date, with robust IRAK4 degradation after a single oral dose lasting for at least six days at all dose levels.
No treatment-related adverse events have been observed to date.
Also, the FDA has lifted the partial clinical hold on the Multiple Ascending Dose (MAD) portion of the Phase 1 trial of KT-474. Kymera plans to initiate repeat dosing in July 2021.
A subsequent cohort in the Phase 1 trial will include up to 20 patients with atopic dermatitis and hidradenitis suppurativa.
Kymera expects to present updated results from the healthy volunteer SAD and MAD portions of the trial in Q4 of 2021.
Kymera will host a conference call and webcast today at 8:00 a.m. ET.
Price Action: KYMR shares are up 8.16% at $48 in the premarket session on the last check Monday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.